Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $660.00

Key Points

• Scotiabank raised Vertex Pharmaceuticals’ price target to $660 from $558 while maintaining a “sector outperform” rating, implying 23.53% upside from the prior close.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and average price target of $595.74; Wells Fargo also raised its target to $650.
• Vertex reported quarterly revenue of $3.44 billion, up 11.8% year over year and above estimates, but EPS of $4.76 missed consensus. Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its target price boosted by equities research analysts at Scotiabank from $558.00 to $660.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "sector outperform" rating on the pharmaceutical company's stock. Scotiabank's price objective would indicate a potential upside of 23.53% from the stock's previous close.

Several other analysts have also recently weighed in on VRTX. Wells Fargo & Company lifted their price objective on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an "overweight" rating in a research note on Tuesday. TD Cowen lifted their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a "buy" rating in a research report on Tuesday. Daiwa Securities Group increased their price target on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group boosted their target price on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a "hold" rating in a report on Tuesday, August 4th. Finally, Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an "outperform" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $595.74.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded down $18.88 during mid-day trading on Tuesday, hitting $534.27. The company's stock had a trading volume of 1,204,990 shares, compared to its average volume of 1,388,479. Vertex Pharmaceuticals has a one year low of $403.16 and a one year high of $568.67. The stock has a market cap of $135.60 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28. The company's fifty day simple moving average is $523.32 and its 200-day simple moving average is $479.96.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the firm earned $4.80 EPS. The company's revenue for the quarter was up 11.8% on a year-over-year basis. On average, sell-side analysts predict that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. United Advisor Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.4% in the 3rd quarter. United Advisor Group LLC now owns 633 shares of the pharmaceutical company's stock valued at $331,000 after purchasing an additional 94 shares in the last quarter. Plancorp LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $254,000. May Hill Capital LLC increased its position in Vertex Pharmaceuticals by 4.2% during the 3rd quarter. May Hill Capital LLC now owns 643 shares of the pharmaceutical company's stock worth $336,000 after purchasing an additional 26 shares in the last quarter. Ashton Thomas Private Wealth LLC increased its position in Vertex Pharmaceuticals by 10.4% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,994 shares of the pharmaceutical company's stock worth $1,565,000 after purchasing an additional 281 shares in the last quarter. Finally, Calamos Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 13.0% in the third quarter. Calamos Wealth Management LLC now owns 1,252 shares of the pharmaceutical company's stock valued at $655,000 after buying an additional 144 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
• Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
• Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
• Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.